Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695502 (bevacizumab biosimilar) + mFOLFOX6 in mCRC
NCT02776683Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of BI 695502 in metastatic colorectal cancer (mCRC), sponsored by Boehringer Ingelheim. Started Jun 2016; status: completed.
02
Drugs
BI 695502
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02776683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776683.